Brief: AB Science FY Operating Loss Narrows To EUR 13.8 Mln

AB Science SA

29/04/2022 17:54

April 29 (Reuters) - AB Science SA  ABS.PA :
    * POSITIVE RESULTS OF PHASE 3 STUDY WITH MASITINIB IN
PROSTATE
CANCER
    * CASH POSITION OF EUR 8.7 MILLION AS OF 31 DECEMBER 2021
    * FY OPERATING LOSS OF EUR 13.8 MILLION, A 6.4% REDUCTION IN
EXPENSES AS COMPARED TO 2020
    * NET LOSS AS OF 31 DECEMBER 2021 WAS EUR 14,463K COMPARED
TO EUR
15,045K AS OF 31 DECEMBER 2020
    * FY REVENUE EUR 1.6 MILLION VERSUS EUR 1.6 MILLION YEAR AGO
    * IN 2021, COVID-19 PANDEMIC HAD A VERY LIMITED IMPACT ON AB
SCIENCE'S CLINICAL DEVELOPMENT PROGRAM
    * AT DATE OF PUBLICATION OF DECEMBER 31, 2021 ANNUAL REPORT,
THERE
WERE NO SIGNIFICANT DELAYS OR IMPACTS ON STUDIES MONITORED IN
RUSSIA AND UKRAINE

Source text for Eikon:  ID:nGNE6kz2pq 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))